42 research outputs found
Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma In Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study
259 INTERIM ANALYSIS OF A PHASE I RADIOIMMUNOTHERAPY STUDY IN ADVANCED RENAL CELL CARCINOMA PATIENTS USING LUTETIUM-177 LABELED MONOCLONAL ANTIBODY CG250
862 RADIOIMMUNOTHERAPY OF ADVANCED RENAL CELL CARCINOMA PATIENTS WITH LUTETIUM-177 LABELED MONOCLONAL ANTIBODY CG250
Management of ureteropelvic junction obstruction in childrend-a roundtable discussion
The investigation, management and follow-up of paediatric ureteropelvic junction obstruction is not standardized. The Young Pediatric Urology Committee of the European Society of Pediatric Urology interviewed five experts in the field on various aspects of management and compared this with published literature
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Item does not contain fulltextBACKGROUND: The Prostate CAncer gene 3 (PCA3) assay has shown promise as an aid in prostate cancer (pCA) diagnosis in identifying men with a high probability of a positive (repeat) biopsy. OBJECTIVE: This study evaluated the clinical utility of the PROGENSA PCA3 assay. DESIGN, SETTING, AND PARTICIPANTS: This European prospective, multicentre study enrolled men with one or two negative biopsies scheduled for repeat biopsy. MEASUREMENTS: After digital rectal examination (DRE), first-catch urine was collected to measure PCA3 mRNA concentration and to calculate the PCA3 score. The PCA3 score was compared to biopsy outcome. The diagnostic accuracy of the PCA3 assay was compared to percent of free prostate-specific antigen (%fPSA). RESULTS AND LIMITATIONS: In 463 men, the positive repeat biopsy rate was 28%. The higher the PCA3 score, the greater the probability of a positive repeat biopsy. The PCA3 score (cut-off of 35) had a greater diagnostic accuracy than %fPSA (cut-off of 25%). The PCA3 score was independent of the number of previous biopsies, age, prostate volume, and total prostate-specific antigen (PSA) level. Moreover, the PCA3 score was significantly higher in men with high-grade prostate intraepithelial neoplasia (HGPIN) versus those without HGPIN, clinical stage T2 versus T1, Gleason score >or=7 versus <7, and "significant" versus "indolent" (clinical stage T1c, PSA density [PSAD] <0.15ng/ml, Gleason score in biopsy <or=6, and percent positive cores <or=33%) pCA. CONCLUSIONS: The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
Contains fulltext :
87749schalken.pdf (publisher's version ) (Closed access
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
Contains fulltext :
81822schalken.pdf (publisher's version ) (Closed access